Tenaya Therapeutics, Inc. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
Tenaya Therapeutics, Inc. (TNYA) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-11.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-03-11
- Tenaya Therapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-12-31 was $0.00.
- Tenaya Therapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-09-30 was $0.00.
- Tenaya Therapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- Tenaya Therapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2024-09-30 was $0.00.
- Tenaya Therapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- Tenaya Therapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $5.30M, a 266.16% increase from fiscal 2023.
- Tenaya Therapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $1.45M, a 34.89% decline from fiscal 2022.
- Tenaya Therapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $2.22M, a 74.01% decline from fiscal 2021.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $0.00 derived: sum of 2 quarters · filed 2026-03-11 | $0.00 10-K · filed 2026-03-11 | |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $0.00 10-Q · filed 2025-11-10 | ||
| 2025-06-30 | $0.00 10-Q · filed 2025-08-06 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $0.00 derived: sum of 2 quarters · filed 2026-03-11 | $5.30M derived: sum of 3 quarters · filed 2026-03-11 | $5.30M 10-K · filed 2026-03-11 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $5.30M derived: sum of 2 quarters · filed 2025-11-10 | $5.30M 10-Q · filed 2025-11-10 | $6.75M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $5.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $5.30M 10-Q · filed 2025-08-06 | $6.75M derived: sum of 3 quarters · filed 2025-08-06 | $6.75M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-14 | $1.45M derived: sum of 2 quarters · filed 2025-03-10 | $1.45M derived: sum of 3 quarters · filed 2025-03-10 | -$145.00K derived: sum of 4 quarters · filed 2025-03-10 |
| 2023-12-31 | $1.45M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | $1.45M derived: sum of 2 quarters · filed 2025-03-10 | -$145.00K derived: sum of 3 quarters · filed 2025-03-10 | $1.45M 10-K · filed 2025-03-10 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$1.59M derived: sum of 2 quarters · filed 2024-11-06 | $0.00 10-Q · filed 2024-11-06 | $0.00 derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | -$1.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $0.00 10-Q · filed 2024-08-08 | $0.00 derived: sum of 3 quarters · filed 2024-08-08 | $0.00 derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $1.59M 10-Q · filed 2024-05-14 | $1.59M derived: sum of 2 quarters · filed 2024-05-14 | $1.59M derived: sum of 3 quarters · filed 2024-05-14 | |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-18 | $0.00 derived: sum of 2 quarters · filed 2024-03-18 | $2.22M 10-K · filed 2024-03-18 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $2.22M 10-Q · filed 2023-11-08 | ||
| 2022-06-30 | $2.22M 10-Q · filed 2023-08-09 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-08 | $0.00 derived: sum of 2 quarters · filed 2023-03-08 | $8.35M derived: sum of 3 quarters · filed 2023-03-08 | $8.56M 10-K · filed 2023-03-08 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $8.35M derived: sum of 2 quarters · filed 2022-11-10 | $8.56M 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $8.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | $8.56M 10-Q · filed 2022-08-10 | ||
| 2021-03-31 | $213.00K 10-Q · filed 2022-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |